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Abstract
Background: Previous studies have shown that upper gastrointestinal cancers are the most common cancers in Caspian Littoral, and rate of
esophageal cancer (EC) in Iranian Turkmens residing in the Eastern part of littoral are among the highest in the world. Our aim was to reassess
the rate 30 years later and following socioeconomic changes in the region.Methods:A comprehensive retrospective search was undertaken to
find all new cancer cases during the 1996–2000 period. Diagnosis of cancer was based on histopathological reports in 68.2%, clinical and/or
radiological evidence in 29.7% and death certificate only (DCO) in 2.1% of the cases. Results: A total of 5143 new cancer cases were
registered of whom 3063 (59.6%) were males. The median (IQR) age was 60 (44–69) years. Age-standardized rates (ASR) for all cancers in
males and females were 134.7 and 104.5 per 100,000, respectively. Based on ASR, the top five common cancers in males (excluding skin
cancer) were cancers of esophagus (43.4), stomach (27.8), colorectal (10.7), bladder (7.8) and oral cavity (6.3), while in females cancer of
esophagus (36.3) was followed by cancers of breast (15.7), stomach (8.3) colorectal (6.6) and cervix (3.6). Conclusion:We conclude that EC
incidence rate has decreased to less than half the rate reported 30 years ago, while the incidence rates of colorectal and breast cancers have
increased significantly.
# 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
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Cancer Detection and Prevention 30 (2006) 14–191. Introduction
Results of a large-scale cancer survey carried out in the
Caspian Littoral in northern Iran during 1968–1971 which
was based on a cancer registry centre set up jointly by the
Institute of Public Health Research of Tehran University
(IPHR) and the International Agency for Research on
Cancer (IARC) have shown that North-eastern Iran is a very
high incidence area for oesophageal cancer [1–4].* Corresponding author. Tel.: +98 21 88 01 29 92; fax: +98 21 22 25 36 35.
E-mail address: malek@ams.ac.ir (R. Malekzadeh).
0361-090X/$30.00 # 2006 International Society for Preventive Oncology. Publ
doi:10.1016/j.cdp.2005.11.002Exceptionally high age-adjusted incidence rates of EC
were found in the eastern part of the survey area (Present
day, Golestan Province), including rates in most eastern
parts of up to 165.5/100,000 in men and 195.3/100,000 in
women [2]. These same studies revealed a more than 10
folds variation in EC rates between the eastern and western
parts of the littoral in areas less than 500 km apart. Until the
past few years there were no comprehensive report about the
current incidence rates of cancer in Iran in general and the
Caspian Littoral in particular. In 2003, the results of first
population-based cancer survey from Ardabil Province in
the western part of the Caspian Littoral were published [5],ished by Elsevier Ltd. All rights reserved.
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this province compared to the reports of 30 years ago.
In this paper we report the result of an active surveillance
for all cancer cases and compare the results with the rates
reported 30 years ago from the Golestan province.2. Material and methods
2.1. Geographic and demographic description
Golestan was previously part of Mazandaran province
but became a separate province in 1997. It is located in
north-eastern part of Iran, south-east to the Caspian Sea,
with an area of 20,893 km2, constituting about 1.3% of the
total area of the country. Golestan Province has consider-
able ecologic and ethnic diversity. It consists of deserts,
mountainous and forestalls areas. The climate is moderate,
damp and Mediterranean. The majority of the male
populations are farmers while more than 87% of the
women are housewives, who occasionally work on the
farms as well. According to the last National Iranian Census
(1995) its population was 1,426,288 of whom 54% live in
rural areas. The major ethnicities within the province are
Persians (40%), Turkmen (32%), Sistanis (also called
Zabolis) (15%) and Azeri Turks (5%). Sixty-seven percent
of the population are younger than 30 (median age = 21
years in the urban areas versus 20 years in the rural areas).
Life expectancy at the time of birth is 69.3 years for the
males and 70.2 years for the females.
According to the 1999 health statistics, there existed one
physician for every 1722 people and there were 18 hospitals
with 1184 beds, 14 outpatient clinics, 11 pathology
laboratories and 28 diagnostic radiology clinics. There
was no radiotherapy facility in the province but an onco-
logist, a gastroenterologist, seven urologists, 32 gynecolo-
gists, 24 surgeons, and 26 internists had the facilities and
abilities for making the diagnosis and providing the
appropriate therapy for the cancer patients in the province
or referring them for further therapy (radiotherapy and other
special cares) to Mashhad (Khorasan), Sari and Babol
(Mazandaran) or Tehran.
2.2. Survey method
In order to conduct the study, the Golestan Cancer
Registry office was established in Gonbad, the second major
city in the province, where the Atrak Clinic, Golestan’s main
referral center for upper gastrointestinal (GI) cancers, is also
located. This registry which is still functional has two
permanent staff members and is run by the Golestan
University of Medical Sciences under the supervision of the
Cancer Registry Unit of the Digestive Diseases Research
Center (DDRC), Tehran University of Medical Sciences
(TUMS). The Cancer Registry Unit of DDRC consists of a
gastroenterologist, two epidemiologists, and two patho-logists. The Medical Ethics Committee of DDRC had
approved the survey methods. The survey team consisted of
three general practitioners and 12 medical students who
were trained to go to the hospitals, pathology laboratories,
diagnostic radiology services, outpatient public and private
clinics to check their records to find cancer cases and
whenever possible to make copies of the documents
according to which the diagnosis of cancer had been made.
These documents were then sent to the registry office in
Gonbad and subsequently to the Cancer Registry Unit in
DDRC in Tehran. Data about name, sex, age at the time of
diagnosis, pathologic diagnosis, and place of residence,
diagnostic methods were collected.
During the 8 months period of (February–September
2001), the survey team collected and compiled data for a
period of 5 years (1996–2000) from 17/18 hospitals, 12/14
of the outpatient clinics, 11/11 of the pathology laboratories
and 7/28 of the radiology clinics. The private radiology
centers recorded the identifying data of subjects and only
occasionally kept the radiological or sonographic reports,
while the public centers, usually located within the
hospitals, had kept the radiology reports for a majority of
the patients. Physicians in all seven districts issued death
certificates in duplicate, one for themselves and one to be
kept by graveyard authorities. The physicians sent their
copies to the Deputy for medical care to receive new death
certificates in Gorgan city and these certificates to be
compiled later. Death certificates of urban areas (for all the
seven cities) were obtained from the office of the provincial
medical care deputy.
The provincial deputy for health (mainly concerned with
rural Health), covering the rural area of the whole province,
conducted annual health censuses each year. This is
performed by behvarzes (auxiliary health care workers in
health houses who are responsible for public health care and
health census of each village) at the beginning of each year
through direct, home to home data collection which
included data about the number of new births and deaths
and enquiries regarding the cause of death. The results of
these censuses, including information about the causes of
death in rural areas, were compiled in the Deputy of Health,
where the final annual death statistics were issued. Data
about rural cancer cases, which seems to be more
comprehensive than urban areas were obtained from the
Census Office in Deputy of Health. A number of Golestan
Province residents seek medical care outside the province,
mainly in Mashhad, Tehran and occasionally in Sari or
Babol in Mazandaran. A through search was done in
medical centers of these cities which provide care for cancer
patients to find any cancer cases from Golestan inhabitants.
The hospital-based cancer registry of the Cancer Institute,
Tehran University of Medical Sciences, currently provides
the most reliable and comprehensive data in this large city.
All the incident cancer cases fromGolestan, recorded in the
Cancer Institutewere also included for the same time period
(1996–2000).
S. Semnani et al. / Cancer Detection and Prevention 30 (2006) 14–1916The collected data were summarized in data sheets and
were coded using the ICD-O 3 (International Classification
of Disease for Oncology), 3rd edition [6]. All data were
alphabetically sorted and duplicate cases with the same
name, sex, age and place were eliminated by manual and
computerized linkage. Each alphabetical group was reas-
sessed manually by two individuals, on two different
occasions. The data were computerized using SPSS
(Statistical Package for Social Sciences) software version
10.0 and M.S. Excel Software with Persian fonts. We
calculated the population at risk based on the annual health
census and then calculated person-years of the population at
risk by using each year method. Age- and sex-specific rates,
crude rates, and age-standardized rates (ASRs) per 100,000
cases were calculated for each site (ICD-O, 3rd) using the
direct method of standardization to the world population [7].3. Results
During the 5-year period (1996–2000), 5143 new cancer
cases were registered from the Golestan Province of whom
3063 were men (59.6%). The median (IQR) age was 60 (44–
69) years. Tables 1 and 2 show the principal cancer sites, age-
specific incidence rates, total number of cancer cases, relative
frequencies as well as the crude rates and ASR for both malesTable 1
Cancer in Golestan Province, Iran, 1996–2000: crude, age-specific, and age-stan
Sites for males % All ages 0–14 15–24 25–
Oral cavity 4.5 137 0.2 1.1 1.
Oropharynx 0.5 16 0.0 0.0 0.
Nasopharynx 0.1 3 0.0 0.0 0.
Hypopharynx 0.2 5 0.0 0.0 0.
Esophagus 27.5 843 0.0 0.4 2.
Stomach 17.7 541 0.1 0.6 1.
Colon/rectum 8.1 247 0.1 1.1 3.
Liver 1.1 33 0.0 0.0 0.
Gallbladder, etc. 0.6 17 0.0 0.0 0.
Pancreas 0.4 12 0.0 0.0 0.
Larynx 0.7 20 0.0 0.0 0.
Bronchus and lung 1.5 46 0.0 0.0 0.
Bone 1.2 36 0.4 1.0 1.
Connective tissue 0.3 10 0.0 0.0 0.
Skin melanoma 0.8 26 0.0 0.4 0.
Other skin 9.6 295 0.3 0.6 2.
Prostate 3.5 106 0.0 0.2 0.
Testis 0.6 18 0.1 0.1 1.
Other male genital 0.1 4 0.0 0.0 0.
Bladder 6.2 189 0.3 2.3 2.
Kidney, etc. 1.3 40 0.2 0.0 0.
Nervous system 2.0 60 1.0 0.7 2.
Thyroid 1.8 56 0.2 0.5 1.
Hodgkin’s disease 0.8 26 0.0 0.0 0.
Non-Hodgkin’s lymphoma 1.3 41 0.4 0.7 0.
Myeloid leukemia 0.7 21 0.0 0.1 0.
Other leukemia 0.5 16 0.6 0.6 0.
Lymphoid leukemia 0.3 10 0.1 0.1 0.
Others 6.2 189 1.3 2.3 2.
All sites 100.0 3063 8.8 13.5 28.and females. Diagnosis of cancer was based on histopathol-
ogy in 68.2%; (percentage of microscopic verification (MV)
for some cancer sites is shown in Table 3), clinical or
radiology in 29.7% and death certificate only (DCO) in 2.1%
of the cases.As determined by the calculatedASR, the topfive
cancers in males (excluding skin cancer) were esophagus
(43.4), stomach (27.8), colorectal (10.7), bladder (7.8) and
oral cavity (6.3), while in the females they were cancers of
esophagus (36.3), breast (15.7), stomach (8.3), colorectal
(6.6) and cervix (3.6). In Table 4 we have compared ASR and
truncated age standardized rate (TASR) for esophageal and
gastric cancer from this study with the previous survey done
by Mahboubi et al. about 30 years ago [2].4. Discussion
According to the last nation-wide annual mortality report
(2000), excluding accidents, cancer is the second cause of
death in Iran after cardiovascular disease. Fifty percent of all
cancer deaths are attributed to GI cancers, and gastric cancer
alone accounts for more than 20% of all deaths due to cancer
[8]. The striking high incidence rates of EC 30 years ago and
an absence of any comprehensive study since then were the
major motivations behind this survey. Our results demon-
strate that GI cancers account for 57% of all cancers in thedardized incidence rates in males
34 35–44 45–54 55–64 65 Crude rate ASR
6 4.7 6.5 22.5 38.9 4.1 6.3
0 0.5 0.5 2.3 7.0 0.5 0.8
0 0.0 0.0 0.8 1.4 0.1 0.2
0 0.0 1.4 0.8 0.7 0.1 0.3
5 12.9 72.4 178.8 274.6 25.2 43.4
4 7.1 24.8 118.9 205.8 16.2 27.8
7 12.6 15.4 45.9 43.8 7.4 10.7
6 1.1 1.9 8.6 7.6 1.0 1.6
2 0.5 1.4 1.6 5.6 0.5 0.8
2 0.3 0.9 1.6 2.8 0.4 0.5
0 0.3 2.3 2.3 7.0 0.6 1.0
2 1.4 2.3 9.3 13.9 1.4 2.2
2 0.5 0.5 4.7 2.8 1.1 1.1
2 0.5 0.0 3.1 1.4 0.3 0.4
4 0.5 2.8 4.7 4.2 0.8 1.2
5 10.1 26.6 50.5 79.9 8.8 14.3
2 0.0 2.3 10.1 57.7 3.2 5.2
6 1.1 0.9 1.6 0.0 0.5 0.6
0 0.0 0.0 1.6 1.4 0.1 0.2
9 4.7 11.2 24.1 41 5.7 7.8
2 0.5 3.7 8.6 9.7 1.2 1.9
3 1.9 2.3 5.4 4.2 1.8 2.0
2 5.7 4.2 2.3 6.3 1.7 2.1
6 1.1 1.9 8.6 7.6 1.0 1.6
8 1.1 3.3 3.9 7.0 1.3 1.7
4 0.3 0.5 0.8 0.7 0.2 0.3
2 0.0 0.5 0.0 1.4 0.5 0.5
2 0.6 0.9 0.8 0.7 0.3 0.4
9 4.7 11.2 24.1 41.0 5.7 7.8
5 69.5 178.4 502.2 821.7 87.5 134.7
S. Semnani et al. / Cancer Detection and Prevention 30 (2006) 14–19 17
Table 2
Cancer in Golestan Province, Iran, 1996–2000: crude, age-specific, and age-standardized incidence rates in females
For females sites % All ages 0–14 15–24 25–34 35–44 45–54 55–64 65 Crude rate ASR
Oral cavity 3.4 70 0.1 0.5 1.0 3.3 4.0 14.7 17.8 2.2 3.5
Oropharynx 0.3 6 0.0 0.0 0.0 0.3 0.5 1.6 1.4 0.2 0.3
Nasopharynx 0.1 2 0.0 0.0 0.0 0.3 0.0 0.9 0.0 0.1 0.1
Hypopharynx 0.2 4 0.0 0.0 0.0 0.0 0.9 0.9 0.8 0.1 0.2
Esophagus 31.0 645 0.2 0.2 2.9 16.6 55.2 180.9 189.0 19.9 36.3
Stomach 7.6 158 0.1 0.4 1.5 3.3 4.9 35.5 60.8 4.9 8.3
Colon and rectum 6.2 129 0.1 0.6 2.5 5.8 8.0 34.6 25.1 4.0 6.6
Liver 0.4 9 0.0 0.0 0.2 0.0 0.9 1.7 3.2 0.3 0.5
Gallbladder, etc. 0.6 13 0.0 0.0 0.2 0.6 1.3 0.9 4.9 0.4 0.7
Pancreas 0.3 6 0.0 0.0 0.0 0.6 0.0 0.0 3.2 0.2 0.3
Larynx 0.1 2 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.1
Bronchus and lung 0.6 12 0.0 0.0 0.2 0.6 0.9 2.6 3.2 0.4 0.6
Bone 0.8 16 0.3 0.5 0.8 0.0 0.4 1.7 1.6 0.5 0.6
Connective tissue 0.1 2 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.1
Skin melanoma 0.6 13 0.0 0.1 0.2 0.3 2.2 1.7 2.4 0.4 0.6
Other skin 6.3 132 0.2 0.6 1.4 6.6 13.4 22.5 32.4 4.1 6.7
Breast 18.1 377 0.0 1.5 13.6 33.7 44.5 30.3 30.8 11.6 15.7
Cervix 3.9 82 0.0 0.2 3.1 5.8 9.4 11.3 7.3 2.5 3.6
Uterus 2.3 47 0.1 0.2 0.6 2.8 6.2 5.2 8.9 1.4 2.2
Ovary 2.9 60 0.3 0.5 1.5 6.1 4.9 8.7 1.6 1.8 2.5
Other female genital 0.9 18 0.0 0.1 0.2 0.0 0.9 5.2 6.5 0.6 1.0
Bladder 1.4 30 0.0 0.0 0.4 1.4 0.4 6.9 11.4 0.9 1.6
Kidney, etc. 0.7 15 0.2 0.0 0.2 0.0 3.1 1.7 2.4 0.5 0.7
Nervous system 1.1 22 0.6 0.1 0.4 0.8 1.3 3.5 1.6 0.7 0.9
Thyroid 1.9 40 0.2 0.2 1.0 4.4 2.2 2.6 5.7 1.2 1.6
Hodgkin lymphomas 0.7 15 0.1 0.5 0.6 0.6 0.9 2.6 3.2 0.5 0.8
Non-Hodgkin lymphomas 2.0 41 0.4 0.4 1.0 1.1 1.8 5.2 4.1 0.9 1.4
Myeloid leukemia 0.6 12 0.2 0.3 0.2 0.3 0.5 1.7 2.4 0.4 0.5
Lymphoid leukemia 2.1 43 0.1 0.1 0.4 0.6 0.9 2.6 1.6 0.4 0.6
Other leukemia 0.9 18 0.6 0.3 0.2 0.6 0.9 2.6 1.6 0.6 0.7
Others 2.0 41 1.7 0.7 0.6 1.4 2.2 0.0 2.4 1.3 1.3
All sites 100.0 2080 7.0 10.1 37.8 99.9 176.8 400.8 454.3 65.9 104.5study region and that upper GI tract malignancies
contributes to 47.8% of all cancers in Golestan in which
esophageal and gastric cancers constitutes 31.2 and 16.6%
of all cancers. These incidence rates of EC are strikinglyTable 3
Percentage of microscopic verification for some cancer sites
Site MV (%) Total
Esophagus 47.7 1488
Stomach 49.6 699
Colon and rectum 95.9 376
Gallbladder 86.7 30
Liver 86.4 42








Brain, nervous system 65.6 82
Thyroid 97.3 96
Hodgkin’s disease 95.1 41
Non-Hodgkin’s lymphoma 97.2 82
Leukaemia 87.3 120different from those reported 30 years ago; also, rates of
colorectal and breast cancers appear to have increased over
this time period.
Almost all economic indices show that over the past 30
years and following the 1979 revolution, living standards
have improved significantly along the entire length of the
Caspian Littoral of Iran. A recent study in the rural and urban
areas of Gonbad District in a region that about 70% were
Turkmen revealed that about 60% of inhabitants were
overweight with a body mass index (BMI) greater than 25
and 25% of them were obese (BMI > 30). In 1970, less than
5% of the people in the rural areas had refrigerators; now it
has increased to more than 90%, which has resulted in better
food storage systems, and decreased consumption of salted
and smoked food [9]. Overall improvements in socio-
economic status including higher incomes, availability of
electricity, access to safe drinking water and natural gas for
heating and cooking, telephone communication and trans-
port coverage of 98% in the urban areas and 92% in the rural
areas in today’s Golestan could be regarded as one of the
main reasons of this sharp decrease in the esophageal
squamous cell carcinoma (ESCC) incidence rates.
Another major reason that could justify this decline is
the fact that in the early 1970s, endoscopy was not available
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Table 4
Comparison of esophageal and stomach cancer ASR and TASR (age-group 35–64) between previous and present study in Golestan
Esophagous Stomach
Male Female Male Female
ASR TASR ASR TASR ASR TASR ASR TASR
Mahboubia 1970 80 165 80 180 NA 31 NA 17
Golestan Surveillance 1996–2000 43 76.8 36 72.7 27.8 42.2 8.3 12.2
NA: not available.
a Estimated rate for Gorgan and Gonbad regions in Mahboubi study (present day Golestan province).and nearly all GI tumors were diagnosed and classified by
clinical symptoms or radiological findings. ESCC, esopha-
geal adenocarcinoma (EAC) and gastric cardia adenocarci-
noma (GCA) all usually present with dysphagia as the
dominant symptom, while patients with gastric noncardia
adenocarcinoma (GNCA) usually do not complain of
dysphagia. Thus, in the 1970s the first three tumors were
probably all grouped and diagnosed as ‘‘EC’’, while only
GNCA had been diagnosed as ‘‘GC’’. According to our
recent endoscopic data [10] if we combine the current
figures for ESCC, EAC and GCA as ‘‘EC’’, the ‘‘EC’’,‘‘GC’’
ratio is still 5:1, similar to the 1970 figures. Therefore, the
difference from cancer registry data obtained 30 years ago is
in part due to the differences between survey techniques and
the fact that in that registry system, the diagnosis of EC was
confirmed histologically in only about 10% of the cases [2],
while in our study diagnosis was based on pathologic
confirmation in 47.7% of cases (Table 3).
It is likely, therefore, that in the 70s, due to the
misclassification of some of the GCs as ECs, the EC had
been over-diagnosed resulting in an under-estimation of the
true incidence of GC. So, the increased incidence of GC in
our survey can be interpreted as an artifact. ESCC was
equally distributed between the two sexes, similar to Linxian
in China, but completely different from the pattern seen in
low-incidence Western Countries, where the incidence of
ESCC is several-fold higher in men [11].
The studies that were conducted in the 1970s in the
southern border of the Caspian Sea showed that areas
mainly inhabited by Turkmen had a much higher incidence
rates of EC compared to the areas resided mainly by
Persians [1,2]. However, it was not known whether within
the high-risk areas the rates were also higher among
Turkmen or not. A recent study [10] suggested that the risk
of ESCC in Turkmen cannot be several-fold higher than the
risk in non-Turkmen and it argues against the existence of
strong Turkmen specific genetic components in the etiology
of ESCC in eastern Golestan. Only 1% of the ESCC cases
were younger than 30 and 4% aged less than 40, another
finding that argues against genetic background as a
predominant etiological factor. Also a recent genetic
polymorphism study failed to show significant variations
in the frequencies of genetic polymorphisms of 10 genes
known to be associated with increased risk of EC among
Turkmen of Iran [12].There is only one recent study [13] from Golestan
published by Saidi et al. in 2000 which reported crude rates
for both male and female and ASR for females higher than
our study but they inadvertently have miscalculated ASR in
males in their report, and this is probably due to
underestimation of over 65 age-group population; it is also
important to know that they have based their calculation on a
total number of 14 EC cases.
Lung cancer ranks seventh in Golestan, which seems to
be very low compared to the rates in other parts of the
country. Smoking rate in the general population of this area
is 19% in men and 0.4% in women [14]. We rechecked our
data and discussed this issue with the local oncologist and
other physicians. They also had the same impression that
lung cancer is relatively uncommon in the province. This
strikingly low rate of lung cancer, especially in a population
with high rates of ESCC, two cancers which are thought to
share some risk factors, need further investigations. One
possible component for this low rate could be the fact that
during the study period there was no pulmonologist
available in the province which may have hampered the
diagnosis of lung cancer. During last 3 years that a
pulmonologist has started to work in the Golestan’s capital
city of Gorgan, the number of diagnosed cases of lung
cancer has increased about 20% but it still ranks sixth among
all cancers according to the data from our ongoing cancer
registry in the province. Further studies should be performed
looking specifically for the reasons of this low rate of lung
cancer in the area.
The increasing ASR for colorectal cancer from 3 to 10
during the same period may also be at least partially due to
improving socioeconomic status and subsequent lifestyle
changes. Prostate cancer which is a common cancer among
males in western countries [15] ranked sixth in Golestan;
this may be partly due to the fact that in the rural areas
people older than 65 years do not receive a full diagnostic
workup when they are sick and a significant number of
deaths in older people are recorded as ‘‘due to old age’’ in
the rural health census.
Golestan, a relatively small newly established province,
has a low rate of migration in and out. It has the advantage of
having astute health authorities who provide the best
cooperation in the ongoing studies. These, together with
having comprehensive rural health infrastructures, make it a
suitable choice for conducting of population-based studies.
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access to all the patient records and were very closely
monitored by expert pathologists and epidemiologists of the
DDRC’s Registry Unit in Tehran. The survey team obtained
copies of pathologic, imaging and endoscopic documents in
the majority of the cases; and the epidemiologists and
pathologists were able to recheck the information, especially
to exclude benign or suspicious cases and to reclassify the
cancers if necessary. Finding of a linear increase in overall
incidence rates by age; and similar to most other parts of the
world, higher rates of colorectal and lung cancer in men than
in women are also two lines of evidence that strengthen the
validity of our results.
One of the shortcomings of our study was its retro-
spective nature in the setting of suboptimal quality medical
records kept in private and, to some extent, in public
hospitals and other medical centers. But the data from the
first year of a new prospective cancer registry, which has
begun since 2002 in East Golestan, shows rates similar to
those in the current study (Malih, unpublished data). Also,
not using the ICD coding system in some of the medical
centers at the time of diagnosis made it impossible to
classify all cancer cases from the exact topographic point of
view. The alphabetical organization of data we used to
eliminate cases with similar names may have resulted in 5–
10% of doubles. Therefore, it is likely that we have
underestimated some tumors and our results should be
regarded as the minimum cancer incidence rates in Golestan.
Despite these shortcomings, we did our best to find all new
cancer cases, and we think that these data are the most
complete and accurate estimate of cancer occurrence that
have been reported up to now from this area.Acknowledgements
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